Insulin Resistance and the Polycystic Ovary Syndrome Revisited: An Update on Mechanisms and Implications
Open accessThe DOI matches its Crossref record; 621 of the 628 references it cites were found in a registry or an index.
Abstract
Polycystic ovary syndrome (PCOS) is now recognized as an important metabolic as well as reproductive disorder conferring substantially increased risk for type 2 diabetes. Affected women have marked insulin resistance, independent of obesity. This article summarizes the state of the science since we last reviewed the field in the Endocrine Reviews in 1997. There is general agreement that obese women with PCOS are insulin resistant, but some groups of lean affected women may have normal insulin sensitivity. There is a post-binding defect in receptor signaling likely due to increased receptor and insulin receptor substrate-1 serine phosphorylation that selectively affects metabolic but not mitogenic pathways in classic insulin target tissues and in the ovary. Constitutive activation of serine kinases in the MAPK-ERK pathway may contribute to resistance to insulin's metabolic actions in skeletal muscle. Insulin functions as a co-gonadotropin through its cognate receptor to modulate ovarian steroidogenesis. Genetic disruption of insulin signaling in the brain has indicated that this pathway is important for ovulation and body weight regulation. These insights have been directly translated into a novel therapy for PCOS with insulin-sensitizing drugs. Furthermore, androgens contribute to insulin resistance in PCOS. PCOS may also have developmental origins due to androgen exposure at critical periods or to intrauterine growth restriction. PCOS is a complex genetic disease, and first-degree relatives have reproductive and metabolic phenotypes. Several PCOS genetic susceptibility loci have been mapped and replicated. Some of the same susceptibility genes contribute to disease risk in Chinese and European PCOS populations, suggesting that PCOS is an ancient trait.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Insulin resistance and hyperinsulinemia, either directly or indirectly, through factors such as adiposity can lead to increase circulating androgen levels (6).”
From Obstructive sleep apnea syndrome in polycystic ovary syndrome: a systematic review and meta-analysis (2025) · cites this paper as [6]
In the citing paper
“Androgen excess favors visceral fat deposition and lipid dysfunction with a vicious cycle of worsening of hyperinsulinemia and insulin resistance (6).”
From Metformin and Combined Oral Contraceptive Pills in the Management of Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis (2024) · cites this paper as [6]
In the citing paper
“primarily due to hyperinsulinemia resulting from insulin resistance, which increases ovarian androgen production [162, 163].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [163]
In the citing paper
“Moreover, women who have both obesity and PCOS exhibit a greater level of insulin resistance in comparison to obese persons who do not have PCOS [53].”
In the citing paper
“Consensus is yet to be achieved in lean women with PCOS as IR is not consistently demonstrated (Diamanti-Kandarakis and Dunaif, 2012).”
From Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic–hyperinsulinaemic clamp studies (2016) · cites this paper as Diamanti-Kandarakis and Dunaif, 2012
13 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s062 · Cited by 13,988
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls
The Wellcome Trust Case Control Consortium, Management Committee, Burton, P. R., Clayton, D. G., Cardon, L. R., Craddock, N., Deloukas, P., Duncanson, A., Kwiatkowski, D. P., McCarthy, M. I., et al. (2007) · Nature · doi:10.1038/nature05911 · Cited by 9,442
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
Finding the missing heritability of complex diseases
Manolio, T. A., Collins, F. S., Cox, N. J., Goldstein, D. B., Hindorff, L. A., Hunter, D. J., McCarthy, M. I., Ramos, E. M., Cardon, L. R., Chakravarti, A., et al. (2009) · Nature · doi:10.1038/nature08494 · Cited by 8,336
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) · Human Reproduction · doi:10.1093/humrep/deh098 · Cited by 6,138
Mechanisms of TGF-β Signaling from Cell Membrane to the Nucleus
Shi, Y., & Massagué, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00432-x · Cited by 5,857
Research works printed but not linked: 5
- Achard, 1921, Le virilisme et son association à l'insuffisance glycolytique (diabète des femmes à barbe), Bull Acad Natl Med (Paris), 86, 51
- Vague, 1947, La différentiation sexuelle. Facteur determinant des formes de l'obesité, Presse Med, 55, 339
- Chereau, 1844, Mémoires pour servir à l'étude des malades ovaires
- Givens, 1992, Historical Overview of the Polycystic Ovary, 3
- Zawadzki, 1992, Diagnostic criteria for polycystic ovary syndrome; towards a rational approach, 377
Cited by
Items 601–700 of 1,006
Mahamed, R. R., Maganhin, C. C., Sasso, G. R. D. S., Simões, M. D. J., Baracat, M. C. P., Baracat, E. C., & Soares, J. M. (2018) · Journal of Ovarian Research · doi:10.1186/s13048-018-0392-1 · Cited by 34
“Cell culture experiments have demonstrated that metformin directly inhibits rat ovarian theca-interstitial cell proliferation through AMPK [40, 42].”
BackgroundMu, L., Li, R., Lai, Y. L., Zhao, Y., & Qiao, J. (2018) · Journal of Endocrinological Investigation · doi:10.1007/s40618-018-0949-2 · Cited by 34
Leung, K. L., Sanchita, S., Pham, C. T., Davis, B. A., Okhovat, M., Ding, X., Dumesic, P., Grogan, T. R., Williams, K. J., Morselli, M., et al. (2020) · Clinical Epigenetics · doi:10.1186/s13148-020-00970-x · Cited by 33
Abdalla, M. A., Shah, N., Deshmukh, H., Sahebkar, A., Östlundh, L., Al-Rifai, R. H., Atkin, S. L., & Sathyapalan, T. (2022) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188221127142 · Cited by 33
Deshmukh, H., Papageorgiou, M., Wells, L., Akbar, S., Strudwick, T., Deshmukh, K., Vitale, S. G., Rigby, A., Vince, R. V., Reid, M., et al. (2023) · Nutrients · doi:10.3390/nu15183872 · Cited by 33
Szkodziak, P. R., Szkodziak, F., Trzeciak, K., Woźniak, S., Mlynarczyk, M., & Paszkowski, T. (2025) · Scientific Reports · doi:10.1038/s41598-025-26718-2 · Cited by 33
“Concurrent adipose inflammation, macrophage infiltration, fibrosis, and tissue expansion further exacerbate metabolic dysfunction 1,2,12–14 .”
InfluentialUdhane, S. S., Legeza, B., Marti, N., Hertig, D., Diserens, G., Nuoffer, J., Vermathen, P., & Flück, C. E. (2017) · Scientific Reports · doi:10.1038/s41598-017-09189-y · Cited by 33
Tosi, F., Molin, F. D., Zamboni, F., Saggiorato, E., Salvagno, G. L., Fiers, T., Kaufman, J., Bonora, E., & Moghetti, P. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa095 · Cited by 33
Kiconco, S., Teede, H. J., Azziz, R., Norman, R. J., & Joham, A. E. (2021) · Seminars in Reproductive Medicine · doi:10.1055/s-0041-1735259 · Cited by 33
Metabolic Features of Women With Polycystic Ovary Syndrome in Latin America: A Systematic Review
Marchesan, L. B., Ramos, R. B., & Spritzer, P. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.759835 · Cited by 33
“While the prevalence of insulin resistance is high in both lean and obese women with PCOS (16), the presence of obesity may exacerbate the development of metabolic comorbidities and cardiovascular risk factors (17–19).”
BackgroundBasic aspects of endometrial receptivity in PCOS patients
Pathare, A. D. S., Hinduja, I. N., & Mahadik, R. C. (2022) · Molecular Biology Reports · doi:10.1007/s11033-021-06976-9 · Cited by 34
“Similarly, the impaired translocation of GLUT-1 vesicles disrupting its function associated with ENR was evidenced by immunohistochemistry findings [56].”
BackgroundKim, J. H., Choi, S., Lee, Y. A., Lee, J., & Kim, S. G. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2021.1328 · Cited by 33
“However, poor disease control with androgen excess can be related to insulin resistance in women [7,21-25].”
BackgroundRole of insulin resistance on fertility – Focus on polycystic ovary syndrome
Vatier, C., Christin‐Maître, S., & Vigouroux, C. (2022) · Annales d Endocrinologie · doi:10.1016/j.ando.2022.04.004 · Cited by 33
Combined Transcriptomic and Metabolomic Analysis of Women with Polycystic Ovary Syndrome
Tian-Min, Y., Suxia, L., Ding, S., Cao, D., Long-Dan, L., & Yeung, W. S. B. (2022) · Disease Markers · doi:10.1155/2022/4000424 · Cited by 33
Shi, J., Hu, K.-L., Li, X., Ge, Y., Xiaojun, Y., & Zhao, J. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01410-y · Cited by 34
“It has been proposed that IR in PCOS is a consequence of an interplay between genetic predispositions and environmental factors [15].”
BackgroundEtrusco, A., Mikuš, M., D’Amato, A., Barra, F., Planinić, P., Goluža, T., Buzzaccarini, G., Marušić, J., Tešanović, M., & Laganà, A. S. (2024) · Biomedicines · doi:10.3390/biomedicines12030653 · Cited by 33
Type B Insulin Resistance Masquerading As Ovarian Hyperthecosis
Brown, R. J., Joseph, J., Cochran, E. K., Gewert, C., Semple, R. K., & Görden, P. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3674 · Cited by 33
Zhai, J., Yao, G., Wang, J., Yang, Q., Wu, L., Chang, Z.-Y., & Sun, Y. (2019) · Reproductive Sciences · doi:10.1177/1933719118820466 · Cited by 34
“It is generally accepted that insulin resistance and secondary hyperinsulinemia have a pivotal role in the pathophysiology of PCOS.(5,6) The endocrine and metabolic abnormalities in patients with PCOS also affect the metabolism and function of the endometrium, which may lead to impaired endometrium receptivity, result…”
BackgroundInfluentialRelationship between the characteristic traits of polycystic ovary syndrome and susceptibility genes
Hong, S.-H., Hong, Y. S., Jeong, K., Chung, H., Lee, H., & Sung, Y.-A. (2020) · Scientific Reports · doi:10.1038/s41598-020-66633-2 · Cited by 32
Juhász, A. E., Stubnya, M. P., Teutsch, B., Gede, N., Hegyi, P., Nyirády, P., Bánhidy, F., Ács, N., & Juhász, R. (2024) · Reproductive Health · doi:10.1186/s12978-024-01758-5 · Cited by 32
“It is also observed that being overweight increases the chance of developing PCOS [5].”
BackgroundYe, Z.-R., Yan, C., Liao, N., & Wen, S.-H. (2023) · Reproductive Sciences · doi:10.1007/s43032-023-01222-y · Cited by 32
“While multiple mechanisms have been proposed for the insulin resistance seen in patients with PCOS, such as decreases in kinase activity, phosphorylation of insulinreceptor substrate, PI3K activity, and glucose transporter translocation [49, 50], impairment of downstream metabolic insulin signaling [51], and increased…”
BackgroundParker, J., O'Brien, C. L., Uppal, T., & Tremellen, K. P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26209926 · Cited by 33
“Insulin-mediated impairment of FSH also downregulates aromatase expression, contributing to androgen excess and decreased ovarian E2 production [147].”
Kazemi, M., Kim, J. Y., Parry, S. A., Azziz, R., & Lujan, M. E. (2020) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2020.12.019 · Cited by 32
Association between Nonalcoholic Fatty Liver Disease and Endocrinopathies: Clinical Implications
Sîngeap, A.-M., Stanciu, C., Huiban, L., Muzica, C. M., Cuciureanu, T., Gîrleanu, I., Chiriac, S. A., Zenovia, S., Năstasă, R., Sfarti, C. V., et al. (2021) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2021/6678142 · Cited by 33
“-e main presumed reasons why PCOS women may have low insulin sensitivity include both defects in the insulin receptors found on the surface of the ovaries and irregular insulin signalling which increases androgen production in theca cells, the primary source of excessive androgen biosynthesis in women with PCOS [33].”
Polycystic Ovarian Syndrome in Adolescents
Adone, A., & Fulmali, D. G. (2023) · Cureus · doi:10.7759/cureus.34183 · Cited by 32
“Figure 1 shows how PCOS leads to insulin resistance [16].”
BackgroundArusoglu, G., Koksal, G., Cinar, N., Tapan, S., Aksoy, D. Y., & Yildiz, B. O. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1526 · Cited by 30
Pasquali, R., Diamanti‐Kandarakis, E., & Gambineri, A. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0374 · Cited by 32
Self-citationΜacut, D., Antić, I. B., Bjekić-Macut, J., Panidis, D., Τζιόμαλος, Κ., Milutinović, D. V., Stanojlović, O. P., Kastratović-Kotlica, B., Petakov, M. S., & Milic, N. M. (2015) · HORMONES · doi:10.14310/horm.2002.1592 · Cited by 32
“forming the risk factors for the metabolic syndrome (MetS).(4) Therefore, PCOS is considered to be a”
BackgroundTang, X., Sun, Z., & Gong, L. (2017) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.13462 · Cited by 31
“In accordance with this, PCOS elevates the risk of type 2 diabetes mellitus and gestational diabetes mellitus.(6)”
BackgroundKazemi, M., Jarrett, B. Y., Parry, S. A., Thalacker‐Mercer, A. E., Hoeger, K. M., Spandorfer, S. D., & Lujan, M. E. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa426 · Cited by 31
Role of inflammatory markers in polycystic ovaries syndrome: In relation to insulin resistance
Alissa, E. M., Algarni, S. A., Khaffji, A. J., & Mansouri, N. M. A. (2021) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.14684 · Cited by 31
“Polycystic ovary syndrome (PCOS) is one of the most frequent endocrinal disorders affecting premenopausal women, with a worldwide prevalence rate of 5%–10%.1 Initially, it was suggested that most of the abnormalities observed in PCOS result from insulin resistance and/or hyperinsulinemia, which affects about 50% of PC…”
BackgroundInfluentialZhuang, C., Wang, Q., Wang, W., Sun, R., Zhang, F., & Yu, J. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.822079 · Cited by 31
Updates on Molecular Targets and Epigenetic-Based Therapies for PCOS
Смирнов, В. В., Beeraka, N. M., Butko, D. Y., Nikolenko, V. N., Bondarev, S., Achkasov, E. E., Sinelnikov, M. Y., & Vikram, P. R. H. (2022) · Reproductive Sciences · doi:10.1007/s43032-022-01013-x · Cited by 33
Non-alcoholic fatty liver disease across endocrinopathies: Interaction with sex hormones
Arefhosseini, S., Ebrahimi‐Mameghani, M., Najafipour, F., & Tutunchi, H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1032361 · Cited by 31
Glintborg, D., Mumm, H., Holst, J. J., & Andersen, M. (2017) · Endocrine Connections · doi:10.1530/ec-17-0034 · Cited by 26
“In meta-analyses, treatment with OCP was associated with unchanged fasting insulin in PCOS (16), but fasting insulin is only a rough measure of insulin resistance (33) and different generation OCPs could have divergent effects on metabolic risk factors (34).”
BackgroundAmini, L., Mojab, F., Jahanfar, S., Sepidarkish, M., Raoofi, Z., & Maleki-Hajiagha, A. (2020) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2019.102245 · Cited by 30
Antonio, L., Pauwels, S., Laurent, M. R., Vanschoubroeck, D., Jans, I., Billen, J., Claessens, F., Decallonne, B., De Neubourg, D., Vermeersch, P., et al. (2018) · International Journal of Endocrinology · doi:10.1155/2018/7956951 · Cited by 30
“Furthermore, these diagnostic criteria do not take into account metabolic parameters, and patients with clearly different metabolic characteristics are diagnosed under the umbrella term of PCOS [5, 6].”
BackgroundHooshmandi, H., Ghadiri‐Anari, A., Ranjbar, A. M., Fallahzadeh, H., Hosseinzadeh, M., & Nadjarzadeh, A. (2024) · Journal of Ovarian Research · doi:10.1186/s13048-024-01446-9 · Cited by 30
“Interestingly, our study revealed that licorice supplementation has beneficial effects on IR as a dependent factor associated with PCOS disease severity [8].”
BackgroundEndocrine and metabolic effects of GLP-1 receptor agonists on women with PCOS, a narrative review
Monney, M., Mavromati, M., Leboulleux, S., & Gariani, K. (2025) · Endocrine Connections · doi:10.1530/ec-24-0529 · Cited by 31
Sharmeen, S., Nomani, H., Taub, E. M., Carlson, H. E., & Yao, Q. (2021) · Clinical Rheumatology · doi:10.1007/s10067-021-05850-0 · Cited by 30
“The etiology of PCOS remains elusive, but one of the potential mechanisms is related to insulin resistance, and hyperandrogenism [21].”
BackgroundKazemi, M., Kim, J. Y., Wan, C., Xiong, J. D., Parry, S. A., Azziz, R., & Lujan, M. E. (2021) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2021.07.032 · Cited by 30
Tulipano, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313068 · Cited by 30
Tarkesh, F., Jahromi, B. N., Hejazi, N., & Hoseini, G. (2022) · BMC Women s Health · doi:10.1186/s12905-022-01825-8 · Cited by 30
“Although the root cause of PCOS is not completely comprehended, insulin resistance (IR) has been reported as the leading cause of PCOS according to a number of studies [8].”
Nisa, K. U., Tarfeen, N., Mir, S. A., Waza, A. A., Ahmad, M. B., & Ganai, B. A. (2023) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-023-01130-7 · Cited by 30
“…of the serine residue of the insulin receptor substrate-1 molecule (IRS-1 ser 312 ) has been witnessed in the obese PCOS women, consequently leading to impaired Insulin receptor signaling (impaired regulation of IRS-1 and PI3K activity) leading to hyper-insulinemia, favoring hyperandrogenism [85].”
Valsamakis, G., Lois, K., Kumar, S., & Mastorakos, G. P. (2013) · HORMONES · doi:10.1007/bf03401302 · Cited by 30
Liu, D. M., Torchen, L. C., Sung, Y., Paparodis, R., Legro, R. S., Grebe, S. K., Singh, R. J., Taylor, R. L., & Dunaif, A. (2014) · Human Reproduction · doi:10.1093/humrep/deu282 · Cited by 29
“The diagnosis of PCOS was made in the probands using the NIH criteria (Legro et al., 1998; Diamanti-Kandarakis and Dunaif, 2012) of elevated circulating testosterone (T) and/or bioavailable T (uT) levels associated with chronic oligomenorrhea, i.e. ≤6 menses per year.”
BackgroundMethodSelf-citationAdiposity and metabolic dysfunction in polycystic ovary syndrome
Sam, S. (2015) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2015-0008 · Cited by 30
“Insulin resistance is an inherent feature of PCOS independent of obesity; however, PCOS and obesity have a synergistic deleterious effect on glucose tolerance [16, 68, 104].”
BackgroundDiagnosis and Management of Polycystic Ovary Syndrome in Adolescent Girls
Lanzo, E. M., Monge, M. C., & Trent, M. (2015) · Pediatric Annals · doi:10.3928/00904481-20150910-10 · Cited by 31
Metabolic inflexibility in women with PCOS is similar to women with type 2 diabetes
Broskey, N. T., Tam, C. S., Sutton, E. F., Altazan, A. D., Burton, J. H., Ravussin, É., & Redman, L. M. (2018) · Nutrition & Metabolism · doi:10.1186/s12986-018-0312-9 · Cited by 30
Wang, Y., He, J., & Yang, J. (2018) · Medical Science Monitor · doi:10.12659/msm.909098 · Cited by 30
“Abnormal gonadotropin secretion was found to be responsible for hyperandrogenism and anovulation [6].”
BackgroundDakshinamoorthy, J., Jain, P., Ramamoorthy, T., Ayyappan, R., & Balasundaram, U. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.10.235 · Cited by 30
Tuccinardi, D., Masi, D., Watanabe, M., Zanghi Buffi, V., De Domenico, F., Berti, S., Cipriani, V., Manco, M., Manfrini, S., & Pagotto, U. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02700-7 · Cited by 29
“Obesity is more prevalent among females with PCOS than in the general population; it contributes to the development of PCOS and worsens [161] its clinical features, primarily due to hyperinsulinemia resulting from insulin resistance, which increases ovarian androgen production [162, 163].”
Liraglutide and polycystic ovary syndrome: is it only a matter of body weight?
Pugliese, G., de Alteriis, G., Muscogiuri, G., Barrea, L., Verde, L., Zumbolo, F., Colao, A., & Savastano, S. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02084-6 · Cited by 29
Muhammed Saeed, A. A., Noreen, S., Awlqadr, F. H., Farooq, M. I., Qadeer, M., Rai, N., Farag, H. A., & Saeed, M. N. (2025) · Journal of Health, Population and Nutrition · doi:10.1186/s41043-025-00899-y · Cited by 29
“More-over, women who have both obesity and PCOS exhibit a greater level of insulin resistance in comparison to obese persons who do not have PCOS [53].”
Metformin: Repurposing Opportunities for Cognitive and Mood Dysfunction
Ying, M., Maruschak, N., Mansur, R., Carvalho, A., Cha, D., & McIntyre, R. (2015) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666141130205514 · Cited by 29
PCOS: update and diagnostic approach
Goldrat, O., & Delbaere, A. (2018) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2018.09.001 · Cited by 29
Przybycień, P., Gąsior‐Perczak, D., & Placha, W. (2022) · Cells · doi:10.3390/cells11162569 · Cited by 29
“Hyperinsulinemia resulting from insulin resistance stimulates ovarian and adrenal androgen secretion and decreases hepatic SHBG synthesis, increasing free androgen levels [41].”
BackgroundCirculating miRNAs in Women with Polycystic Ovary Syndrome: A Longitudinal Cohort Study
Udesen, P. B., Sørensen, A. E., Svendsen, R. P., Frisk, N. L. S., Hess, A. L., Aziz, M., Wissing, M. L., Englund, A. L. M., & Dalgaard, L. T. (2023) · Cells · doi:10.3390/cells12070983 · Cited by 29
Chakraborty, S., Anand, S., Coe, S. T., Reh, B., & Bhandari, R. K. (2023) · Environmental Science & Technology · doi:10.1021/acs.est.3c01922 · Cited by 29
Polycystic Ovary Syndrome: Features, Diagnostic Criteria and Treatments
Gullo, G. (2014) · Endocrinology & Metabolic Syndrome · doi:10.4172/2161-1017.1000136 · Cited by 29
“Insulin resistance is another metabolic characteristic frequently associated with PCOS [81].”
BackgroundMetabolic syndrome in infertile women with polycystic ovarian syndrome
Madani, T., Hosseini, R., Ramezanali, F., Khalili, G., Jahangiri, N., Ahmadi, J., Rastegar, F., & Zolfaghari, Z. (2016) · Archives of Endocrinology and Metabolism · doi:10.1590/2359-3997000000135 · Cited by 29
“Insulin resistance (IR) plays an important role in pathophysiology of PCOS (2,3).”
BackgroundPaschou, S. Α., Palioura, E., Ioannidis, D., Anagnostis, P. G., Panagiotakou, A., Loi, V., Karageorgos, G., Goulis, D. G., & Vryonidou, A. (2017) · Endocrine Connections · doi:10.1530/ec-17-0239 · Cited by 29
The tempo of human childhood: a maternal foot on the accelerator, a paternal foot on the brake
Kotler, J., & Haig, D. (2018) · Evolutionary Anthropology Issues News and Reviews · doi:10.1002/evan.21579 · Cited by 30
Li, G., Huang, W., Zhang, L., Tian, Z., Zheng, W., Wang, T., Zhang, T., & Zhang, W. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3003 · Cited by 29
“Polycystic ovarian syndrome (PCOS) is the most common reproductive disorder in women of childbearing age and is characterized by oligoovulation or anovulation, hyperandrogenemia or hyperandrogenism, and/or polycystic ovarian morphology.(1,2) In addition to reproductive abnormalities, women with PCOS are also at risk f…”
BackgroundHiam, D., Patten, R. K., Gibson‐Helm, M. E., Moreno‐Asso, A., McIlvenna, L. C., Levinger, I., Harrison, C. L., Moran, L., Joham, A. E., Parker, A. G., et al. (2019) · Trials · doi:10.1186/s13063-019-3313-8 · Cited by 29
Jiang, Y., Qi, J., Xue, X., Huang, R., Zheng, J., Liu, W., Yin, H., & Li, S. (2019) · Gynecological Endocrinology · doi:10.1080/09513590.2019.1698026 · Cited by 29
“Insulin resistance is also highly prevalent in PCOS, even among lean women [4], and another core pathophysiologic feature of PCOS is hyperandrogenism.”
BackgroundWang, L., Luo, X., Wang, Q., Lv, Q., Wu, P., Liu, W., & Chen, X. (2021) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2021.32.e70 · Cited by 29
“Obesity, IR and chronic unopposed exposure of endometrium to estrogen, which are considered risk factors of EC, also present in PCOS patients [11-14].”
BackgroundHeidarzadehpilehrood, R., Hamid, H. A., & Pirhoushiaran, M. (2025) · Metabolism Open · doi:10.1016/j.metop.2024.100343 · Cited by 28
“Such a defect is probably dependent on the modulation of VDR polymorphism that may influence insulin receptor signaling pathways and contribute to the metabolic phenotype of PCOS [45].”
Yang, B., Gong, M., Zhu, X., Luo, Y., LI, R. C., Meng, H., & Wang, Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1514093 · Cited by 28
He, Q., Wu, W., Chen, J., Zhou, H., Ding, G., Lai, S., Kuo, A., Wan, H., Lin, B., Wu, H., et al. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101660 · Cited by 28
Dey, A., Dhadhal, S., Maharjan, R., Nagar, P. S., & Nampoothiri, L. P. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115161 · Cited by 28
Luo, Z., Wang, L., Wang, Y., Fan, Y., Jiang, L., Xu, X. P., Du, Y., & Hao, G. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12030818 · Cited by 28
“Insulin functions physiologically as a co-gonadotropin to regulate follicle growth and development [7].”
BackgroundGurule, S. C., Sustaita-Monroe, J. F., Padmanabhan, V., & Cardoso, R. C. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1096187 · Cited by 28
Zhao, H., Zhou, D., Liu, C., & Zhang, L. (2023) · International Journal of Women s Health · doi:10.2147/ijwh.s393594 · Cited by 28
Decourt, C., Watanabe, Y., Evans, M. C., Inglis, M. A., Fisher, L. C., Jasoni, C. L., Campbell, R. E., & Anderson, G. M. (2023) · Endocrinology · doi:10.1210/endocr/bqad077 · Cited by 28
Jiang, H., Si, M., Tian, T., Shi, H., Huang, N., Chi, H., Yang, R. J., Long, X., & Qiao, J. (2023) · European journal of medical research · doi:10.1186/s40001-023-01174-8 · Cited by 28
“The pathogenesis of PCOS is complex, including genetic and epigenetic susceptibility, hypothalamic and ovarian dysfunction, hyperandrogenism, hyperinsulinemia, and adiposity-related mechanisms [2, 7].”
BackgroundZhou, Y., Wu, Y., Chong, C., Zhong, S.-M., Wang, Z., Qin, X., Liu, Z., Liu, J.-Y., & Song, J. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e18741 · Cited by 28
“Furthermore, androgen excess is often related to IR in obese women, especially those with PCOS [50].”
BackgroundLiu, J., Su, H., Jin, X., Wang, L., & Huang, J. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1209614 · Cited by 28
“(43).”
Emerging pollutants in etiology and pathophysiology of polycystic ovary syndrome
Gautam, R., Parambil, A. M., Patel, A. K., & Arora, T. K. (2023) · Reproductive Toxicology · doi:10.1016/j.reprotox.2023.108515 · Cited by 28
New insights on mitochondrial heteroplasmy observed in ovarian diseases
Zhou, Y., Jin, Y., Wu, T., Wang, Y., Dong, Y., Chen, P., Hu, C., Pan, N., Ye, C., Shen, L., et al. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2023.11.033 · Cited by 28
“Polycystic ovary syndrome (PCOS), a reproductive, endocrine, and metabolic disorder, has been reported to occur in 5 %–20 % of premenopausal women worldwide and is one of the leading causes of female infertility [34].”
BackgroundDavinelli, S., Nicolosi, D., Cesare, C. D., Scapagnini, G., & Marco, R. D. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9040987 · Cited by 28
“A higher body mass index (BMI) exacerbates InsR in PCOS women more than among those without PCOS [19,20].”
BackgroundNorman, A. W., & Henry, H. L. (2014) · Elsevier eBooks · doi:10.1016/b978-0-08-091906-5.00013-6 · Cited by 28
Actkins, K. V., Singh, K., Hucks, D., Velez Edwards, D. R., Aldrich, M., Cha, J., Wellons, M., & Davis, L. K. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa675 · Cited by 27
Gautam, R., Maan, P., Patel, A. K., Vasudevan, S., & Arora, T. K. (2024) · Clinical Nutrition · doi:10.1016/j.clnu.2024.10.028 · Cited by 28
Aye, M. M., Butler, A. E., Kilpatrick, E. S., Kirk, R., Vince, R. V., Rigby, A. S., Sandeman, D. D., & Atkin, S. L. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00592 · Cited by 27
Torshizi, F. F., Chamani, M., Khodaei, H. R., Sadeghi, A. A., Hejazi, S. H., & Heravi, R. M. (2020) · PubMed Central · doi:10.22038/ijbms.2019.36004.8586 · Cited by 27
“Unfortunately, studies on uterine weight and effect of IR on uterine weight in PCOS are limited, and some studies classified uterus as a target tissue for IR (31).”
BackgroundBennett, C., Mansfield, D. R., Mo, L., Joham, A. E., Cain, S. W., Blumfield, M., Hodge, A. M., & Moran, L. (2021) · British Journal Of Nutrition · doi:10.1017/s0007114521002361 · Cited by 27
“mechanistically distinct from obesity-associated insulin resistance (8) in the majority of women with PCOS, regardless of body mass index (BMI) (9), and worsens the clinical presentation of the syndrome.”
Polycystic Ovary Syndrome and the Neuroendocrine Consequences of Androgen Excess
Silva, M. S. B., & Campbell, R. E. (2022) · Comprehensive physiology · doi:10.1002/cphy.c210025 · Cited by 28
Zuo, L., Hai, Y., Zhang, R., Zuo, B., Tian, J., Li, P., Ke, X., Wang, M., Ren, L., Li, X., et al. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175825 · Cited by 27
Kityo, A., & Lee, S. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01981-2 · Cited by 27
“Insulin resistance primarily contributes to the development of various health conditions, such as cardio-metabolic diseases [4–6], polycystic ovary syndrome [6], Alzheimer’s disease, chronic kidney disease (CKD) [7], and cancer [8].”
BackgroundSteroid Metabolomic Signature of Insulin Resistance in Childhood Obesity
Gawlik, A., Shmoish, M., Hartmann, M. F., Wudy, S. A., & Hochberg, Z. (2019) · Diabetes Care · doi:10.2337/dc19-1189 · Cited by 27
“The former has been reported in conjunction with polycystic ovary syndrome, as previously reviewed (17).”
BackgroundVaspin, a novel adipokine in woman granulosa cells physiology and PCOS pathogenesis?
Bongrani, A., Mellouk, N., Ramé, C., Cornuau, M., Guérif, F., Froment, P., & Dupont, J. (2021) · Journal of Endocrinology · doi:10.1530/joe-20-0550 · Cited by 27
Kazemi, M., Pierson, R. A., Parry, S. A., Kaviani, M., & Chilibeck, P. D. (2021) · Obesity Reviews · doi:10.1111/obr.13255 · Cited by 24
“Namely, poor glucoregulatory status, characterized by abnormal glu- cose and insulin levels secondary to insulin resistance (IR) and excessive fat mass, is a critical pathophysiological factor in PCOS.6,10,19 There is, however, a paucity of evidence on other components of body composition (i.e., muscle mass), which co…”
BackgroundInfluentialHuffman, A. M., Rezq, S., Basnet, J., Cardozo, L. L. Y., & Romero, D. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094472 · Cited by 27
“Given the prevalence of insulin resistance in hyperandrogenemic PCOS is estimated in approximately 40–70% of women [50] and that the nervous and musculoskeletal systems are targets in COVID-19 infection, the skeletal muscle’s androgen-mediated impairment of glucose homeostasis may be a relevant cofactor in metabolic r…”
BackgroundJacewicz‐Święcka, M., Wołczyński, S., & Kowalska, I. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10102101 · Cited by 27
“They are responsible for the overproduction of ovarian and adrenal androgens and decreased sex hormone-binding globulin (SHBG) concentration [9–13], which in turn leads to an increase in androgen bioavailability [14,15].”
BackgroundLi, X., Hu, S., Zhu, Q., Yao, G., Yao, J., Li, J., Wang, Y., Ding, Y., Qi, J., Xu, R., et al. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154749 · Cited by 26
Shi, M., Li, X., Xing, L., Li, Z., Zhou, S., Wang, Z., Zou, X., She, Y., Zhao, R., & Qin, D. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16121556 · Cited by 26
Apoptosis in polycystic ovary syndrome: Mechanisms and therapeutic implications
Yang, L.-K., Ma, W., Wang, X., Chen, H.-R., Jiang, Y., & Sun, H. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123394 · Cited by 26
Adipose-androgen crosstalk in polycystic ovary syndrome: mechanisms and therapeutic implications
Ni, M., Lei, H., Ye, T., & Wang, Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1731179 · Cited by 28
Hong, S., Sung, Y., Hong, Y. S., Jeong, K., Chung, H., & Lee, H. (2017) · Clinical Endocrinology · doi:10.1111/cen.13380 · Cited by 26
Metadata
- Authors
- Diamanti-Kandarakis, E., & Dunaif, A.
- Affiliations
- Medical School, University of Athens (E.D.-K.), Athens GR-14578, Greece
- Northwestern University (US)
- ORCID
- Dunaif, Andrea
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2012-10-12
- Volume
- 33
- Issue
- 6
- Pages
- 981-1030
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- PMC
- PMC5393155
- OpenAlex
- W1967263394
- Semantic Scholar
- b2b7fa060bf61f261edf17bef51cbbbd222742e0
- Cited by
- 1,947
- References
- 628
- Citations by year
- 2026: 183 · 2025: 178 · 2024: 182 · 2023: 221 · 2022: 191 · 2021: 184 · 2020: 136 · 2019: 140 · 2018: 108 · 2017: 97 · 2016: 96 · 2015: 92 · 2014: 91 · 2013: 43 · 2012: 4
- FWCI
- 9.98
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Endocrine Reviews (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK073411)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (P50HD044405, R01HD057223, U54HD034449)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
- Keywords
- polycystic ovary syndrome, insulin resistance, insulin receptor signaling, MAPK/ERK pathway, skeletal muscle insulin sensitivity, ovarian steroidogenesis, ovulation, brain insulin signaling, body weight regulation, insulin-sensitizing drugs, androgens, developmental origins of health and disease, fetal growth restriction, genetic susceptibility loci, type 2 diabetes risk, lean PCOS
- MeSH terms
- Female, Humans, Insulin Resistance, Phenotype, Polycystic Ovary Syndrome, Reproduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.